CTLA4 and cancer: As expected, we found that the high-DEPTH2-score (> median) tumors showed a lower response rate to ICIs than the low-DEPTH2-score (< median) tumors in four cancer cohorts receiving anti-PD-1/PD-L1/CTLA-4 immunotherapies (Allen cohort: 5% versus 31.6%; Snyder cohort: 12.5% versus 42.9%; Miao cohort: 12.5% versus 37.5%; Jung cohort: 15.4% versus 46.2%) (Fig. 4D).